Rallybio

Rallybio

Biotechnology Research

New Haven, Connecticut 4,427 followers

Unimagined therapies. Undreamed outcomes.

About us

We are making science’s hardest obstacles our highest priority. Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward as we strive to develop and deliver the truly transformational. Read our Community Guidelines here: https://bit.ly/RLYBCGs

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
New Haven, Connecticut
Type
Public Company
Founded
2018
Specialties
Rare Disease

Locations

  • Primary

    234 Church Street

    Suite 1020

    New Haven, Connecticut 06510, US

    Get directions

Employees at Rallybio

Updates

  • Rallybio reposted this

    View organization page for Soft Bones, Inc., graphic

    167 followers

    Today is World HPP Day! It’s our chance to shine a light on this rare disease. For those who don’t know, hypophosphatasia is caused by a mutation in the ALPL (TNSALP) gene. Low alkaline phosphatase (ALP) levels on a standard blood panel can be a sign of HPP. As research advances, we're uncovering the broader implications of HPP and how it goes beyond bones and teeth. Our new app, myHPP, is already helping us to better understand symptoms that will drive future research initiatives. Together we can change the trajectory of HPP! Help support our mission by donating $15 to celebrate our 15th anniversary. Visit our World HPP Day page to donate. https://lnkd.in/eMjrm-Ke

  • View organization page for Rallybio, graphic

    4,427 followers

    FNAIT is officially on notice 📣 today, as we’ve announced the CTA approval of our lead program, RLYB212, to move into a Phase 2 trial in pregnant women at higher risk of alloimmunization and FNAIT.    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare immune disorder in which a mother's body develops an antigen response against her baby's platelets and can cause uncontrolled bleeding or death in mothers, fetuses and newborns.     More than 30,000 pregnancies are at risk every year, and this trial is the next step in advancing RLYB212 aimed at preventing maternal alloimmunization and FNAIT.    Learn more about what's coming up next and how we're working towards the prevention of this #raredisease for pregnant women everywhere:

    Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT | Rallybio

    Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT | Rallybio

    investors.rallybio.com

  • View organization page for Rallybio, graphic

    4,427 followers

    🧑🔬 Amanda Hayward, Head of Global Business Development presented our research, in partnership with HealthLumen, on quantifying the proportion of women at risk of an FNAIT pregnancy in diverse populations in the United States at NORD today.     The study reveals key findings on fetal/neonatal alloimmune thrombocytopenia (FNAIT) risk across diverse ancestries for the first time.     ˃˃ Using genetic data, researchers found that nearly 20,000 pregnancies in the U.S. are at higher risk for FNAIT each year—far more than previously estimated.    ˃˃ The study highlights that non-White populations also carry significant FNAIT risk, challenging past assumptions.    ˃˃ These findings make a compelling case for universal screening of pregnant women for FNAIT risk, regardless of race or ethnicity, and we’re proud to play a part in advocating for a future where this is the norm.     #HealthEquity #FNAIT #MaternalHealth #NORD #NORD24  

    • No alternative text description for this image
  • View organization page for Rallybio, graphic

    4,427 followers

    A recent study examined delivery hospitalizations from 2016-2019, uncovering significant racial and ethnic disparities in severe maternal morbidity (SMM) across various U.S. communities. Examples of SMM include: heart attack, heart failure, eclampsia, sepsis/blood infection, and hysterectomy.  Key findings: 👉 Non-Hispanic Black women face notably higher risks of SMM, regardless of their community's income level or location. 👉 In urban areas, black women are 88% more likely to experience SMM compared to white women. 👉 Disparities persist even in the highest-income communities, where black women have over twice the odds of SMM compared to their White counterparts. These results highlight the urgent need for tailored healthcare strategies to address systemic inequities in maternal health.  https://lnkd.in/gy7HEZNY As we continue working to improve maternal and fetal health, you can learn more about our efforts to address disparities in another critical area: fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in diverse ancestries. Read more here: https://lnkd.in/gKce2vJz #MaternalHealth #HealthEquity #PublicHealth #HealthcareResearch

    Community level factors and racial inequities in delivery hospitalizations involving severe maternal morbidity in the United States, 2016–2019 - Scientific Reports

    Community level factors and racial inequities in delivery hospitalizations involving severe maternal morbidity in the United States, 2016–2019 - Scientific Reports

    nature.com

  • View organization page for Rallybio, graphic

    4,427 followers

    We're honored to present our latest data with our partners Exscientia and Millán Lab, validating ENPP1 inhibition as a therapeutic approach to late-onset HPP. More to come later this year on our differentiated ENPP1 inhibitor, and how we're coming together to address the significant unmet patient need in this space.

    View organization page for Exscientia, graphic

    48,896 followers

    Our collaborators from Professor Millán’s Lab at Sanford Burnham Prebys presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting today, showing for the first time that ENPP1 is a druggable target for late-onset hypophosphatasia (HPP), a rare and often severe disease. In in vivo studies using our AI-designed tool ENPP1 inhibitor compound, REV101, pyrophosphate (PPi) was significantly lowered to normal concentrations and improvements in mineralisation of bones were shown, which are key functional readouts for disease pathology. Together with Rallybio, we’re developing an ENPP1 inhibitor with improved properties compared with REV101 as a differentiated therapy to address unmet need in patients with HPP. We look forward to sharing more information with you soon. Download our ASBMR poster here: https://bit.ly/EXAI_ASBMR #rarediseases #AI #drugdiscovery #ASBMR2024

    • No alternative text description for this image
  • View organization page for Rallybio, graphic

    4,427 followers

    📣 Exciting news from Rallybio! Today at #ASBMR2024 with our partners Exscientia and Millán Lab, we debuted promising nonclinical data supporting ENPP1 inhibition as a therapeutic approach for hypophosphatasia (HPP) for the first time. Thanks to Dr. José Luis Millán for presenting these findings - With the significant unmet patient need, especially among adults, our findings bring hope for a potential new treatment that could improve the lives of those battling this devastating rare disease.     We're encouraged to see this data as we continue to work with Exscientia on an ENPP1 inhibitor with improved properties compared with REV101 as a differentiated therapy to address the unmet need in patients with HPP. We expect to have more to share on our inhibitor development candidate later this year - for now, download our poster here to take a closer look: https://lnkd.in/eesRGgsr   #RareDisease #HPP #ASBMR2024 

    • No alternative text description for this image
  • View organization page for Rallybio, graphic

    4,427 followers

     We are proud to announce that Rallybio is a 2024 Fierce 50 report honoree. 👏 The Fierce 50 recognizes companies and individuals who have demonstrated a steadfast commitment to innovation, equity, and improving lives. Being named to this year’s list underscores our relentless focus on tackling FNAIT and other rare diseases that affect those most at risk. Read more about this year’s Innovation honorees here: https://lnkd.in/e7RE5ZZg 

    Rallybio

    Rallybio

    fiercepharma.com

  • View organization page for Rallybio, graphic

    4,427 followers

    🗣️ For those attending the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference: Rallybio’s Co-founder and CEO Stephen Uden will be presenting a corporate overview on Tuesday, 9/10 at 11:00 a.m. ET. Don’t miss it! Not attending the 26th? No problem! Head to our website's Events and Presentations section to listen to the live webcast the next 30 days: https://lnkd.in/gXZmHG8d #RareDiesease #HCWainwright 

    Events | Rallybio

    Events | Rallybio

    investors.rallybio.com

Similar pages

Browse jobs

Stock

RLYB

NASDAQ

20 minutes delay

$1.02

Open
1.01
Low
0.995
High
1.06

Data from Refinitiv

See more info on Bing

Funding